Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1627223/000156459019040478/cc-10q_20190930.htm
May 2022
April 2022
March 2022
February 2022
February 2022
December 2021
December 2021
November 2021
October 2021
October 2021
EXHIBIT 99.1
|
The Chemours Company Reports Third Quarter 2019 Results
Committed to Core Growth Strategy and Managing Uncertain Macroeconomic Conditions
WILMINGTON, Del., Nov. 4, 2019 /PRNewswire/ --
Third Quarter 2019 Results
|
• |
Net Sales of $1.4 billion |
|
• |
Net Income of $76 million, with diluted EPS of $0.46 |
|
• |
Adjusted Net Income of $98 million, with diluted Adjusted EPS of $0.59 |
|
• |
Adjusted EBITDA of $248 million |
|
• |
Free Cash Flow of $160 million |
Other Highlights
|
• |
Published our second annual Corporate Responsibility Commitment (CRC) report |
|
• |
Announced the launch of a new Ti-Pure™ product for the high-quality, specialty ink market |
The Chemours Company (Chemours) (NYSE: CC), a global chemistry company with leading market positions in Fluoroproducts, Chemical Solutions and Titanium Technologies, today announced its financial results for the third quarter 2019.
"Our results in the third quarter reflect a weakening macro-economic environment that had an adverse impact on performance across the business," said Chemours President and CEO Mark Vergnano. "Despite that, we continue to make progress on our core business imperatives, including Ti-Pure™ value stabilization, Opteon™ adoption, and Fluoropolymers application development. As part of our ongoing efforts to improve operating efficiencies, we are making several restructuring and portfolio changes across Chemours, including the shutdown of our Methylamines and Methylamides business."
Third quarter 2019 net sales were $1.4 billion in comparison to $1.6 billion in the prior-year quarter. Results were driven primarily by lower volume in Titanium Technologies and lower volume and price in Fluoroproducts, resulting in a 15 percent decrease in net sales. Currency was a small headwind in the quarter. Third quarter net income was $76 million, or $0.46 per diluted share, inclusive of restructuring, asset related, and other charges of $34 million. Adjusted EBITDA for the third quarter 2019 was $248 million in comparison to $435 million in the previous year's third quarter, a result of lower volumes and fixed cost under-absorption in Titanium Technologies, lower margins in Fluoroproducts, and reduced F-Gas quota sales.
Fluoroproducts
Fluoroproducts segment net sales in the third quarter were $636 million in comparison to $682 million in the prior-year quarter. The continued impact of illegal imports of HFC refrigerants into the EU, softer base refrigerants demand, and macro-economic weakness more than offset the positive impact of adoption of Opteon™ mobile refrigerants and the increased sales of high-grade Fluoropolymers. Price and volume declined 4 percent and 2 percent, respectively, on a year-over-year basis. Segment Adjusted EBITDA of $122 million decreased 33 percent versus the prior-year quarter, primarily due to lower net sales and lower F-Gas quota sales.
Chemical Solutions
Chemical Solutions segment net sales in the third quarter were $140 million in comparison to $155 million in the prior-year quarter. Prices were lower year-over-year primarily driven by mix and lower cost pass-throughs in Performance Chemicals and Intermediates. Third quarter 2019 segment Adjusted EBITDA of $23 million decreased 4 percent versus the prior-year quarter, reflecting price headwinds partially offset by increased other income from licensing agreements.
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1627223/000156459019040478/cc-10q_20190930.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Chemours Co.
Chemours Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:
Rating
Learn More![]()
The components of the decrease in our net sales by segment for the nine months ended September 30, 2019 were as follows: in our Fluoroproducts segment, volume was down 5%, price declined 2%, and unfavorable currency movements added a 1% headwind to segment net sales; in our Chemical Solutions segment, volume and price decline by 8% and 3%, respectively; and, in our Titanium Technologies segment, volume was down 30%, while unfavorable currency movements added a 1% headwind to segment net sales.
The components of the decrease in our net sales by segment for the three months ended September 30, 2019 were as follows: in our Fluoroproducts segment, volume was down 2%, price declined 4%, and unfavorable currency movements added a 1% headwind to segment net sales; in our Chemical Solutions segment, volume was up 1% and price declined 11%; and, in our Titanium Technologies segment, volume and price were down 20% and 2%, respectively.
Our financial policy seeks to: (i) selectively invest in organic and inorganic growth to enhance our portfolio, including certain strategic capital investments; (ii) return cash to shareholders through dividends and share repurchases; and, (iii) maintain appropriate leverage by using free cash flows to repay outstanding borrowings.
These decreases were primarily attributable to the aforementioned decreases in volume, price, and unfavorable currency movements.
To supplement our financial information presented in accordance with GAAP, we provide the following non-GAAP financial measures - Adjusted EBITDA, Adjusted Net Income, Adjusted Earnings per Share ("EPS"), Free Cash Flows ("FCF"), and Return on Invested Capital ("ROIC") - in order to clarify and provide investors with a better understanding of our performance when analyzing changes in our underlying business between reporting periods and provide for greater transparency with respect to supplemental information used by management in its financial and operational decision-making.
The decrease in segment net...Read more
For the nine months ended...Read more
These increases were attributable to...Read more
During the third quarter of...Read more
These decreases were primarily attributable...Read more
57 In accordance with the...Read more
Our selling, general, and administrative...Read more
Our SG&A expense decreased by...Read more
Our presentation of Adjusted EBITDA,...Read more
The decrease in our other...Read more
Factors that could cause or...Read more
63 The following table sets...Read more
The change in the Company's...Read more
These valuation models incorporated a...Read more
The decrease in our SG&A...Read more
48 The following chart sets...Read more
50 The following chart sets...Read more
52 The following chart sets...Read more
The decrease in our SG&A...Read more
The decrease in segment net...Read more
Corporate and Other costs decreased...Read more
The decrease in segment net...Read more
The decrease in cash flows...Read more
The decrease in our equity...Read more
The decrease in our equity...Read more
The proceeds were used to...Read more
The decrease in segment net...Read more
Additionally, our Corporate Responsibility commitment...Read more
The decrease in our other...Read more
As final clean-up activities for...Read more
The decreases in our COGS...Read more
Our other accrued liabilities decreased...Read more
The decrease in segment net...Read more
Consistent with our values and...Read more
For the nine months ended...Read more
We believe the presentation of...Read more
Illegal imports of legacy hydrofluorocarbon...Read more
Illegal imports of legacy hydrofluorocarbon...Read more
These declines primarily resulted from...Read more
Adjusted EBITDA and Adjusted EBITDA...Read more
Remaining work beyond continued operation...Read more
We utilize Adjusted EBITDA as...Read more
The excess of the purchase...Read more
The increase in our other...Read more
We call this responsible chemistry...Read more
The impact of lower sales...Read more
Price (4 )% (2 )%...Read more
Price (11 )% (3 )%...Read more
Price (2 )% Volume (20...Read more
Discount rate and market multiple...Read more
Unfavorable currency movements added a...Read more
Unfavorable currency movements added a...Read more
The non-GAAP financial measures we...Read more
The increase in our interest...Read more
Having received this, the insurance...Read more
The following table sets forth...Read more
At September 30, 2019 and...Read more
Our equity in earnings of...Read more
58 In large part, because...Read more
Our inventories increased by $76...Read more
In addition, portfolio changes, such...Read more
The change in the Company's...Read more
Adjusted earnings before interest, taxes,...Read more
To achieve this goal, we...Read more
Adjusted EBITDA and Adjusted EBITDA...Read more
Adjusted EBITDA and Adjusted EBITDA...Read more
Our obligations to our suppliers,...Read more
Such charges could have a...Read more
Additionally, we made cash payments...Read more
As more sites advance from...Read more
The decrease in segment net...Read more
A reconciliation of Adjusted EBITDA...Read more
The increase in our interest...Read more
Our prepaid expenses and other...Read more
The net borrowings under the...Read more
The decrease in our accounts...Read more
The lawsuit requests that the...Read more
Therefore, considerable uncertainty exists with...Read more
We subsequently repaid the revolver...Read more
These cash outflows were somewhat...Read more
Our accounts payable decreased by...Read more
We anticipate making significant payments...Read more
The division into three zones...Read more
Under these agreements, the financial...Read more
Chemours tests its goodwill for...Read more
The approximate 440-acre site is...Read more
(2) For the three and...Read more
More recently, in March 2017,...Read more
Our interest expense, net increased...Read more
The amount of impairment loss...Read more
47 Our provisions for income...Read more
We expect that our future...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Chemours Co provided additional information to their SEC Filing as exhibits
Ticker: CC
CIK: 1627223
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-19-040478
Submitted to the SEC: Tue Nov 05 2019 12:11:39 PM EST
Accepted by the SEC: Tue Nov 05 2019
Period: Monday, September 30, 2019
Industry: Chemicals And Allied Products